EGFR and neoplasm: By doing so, BsAbs can achieve dual pathway inhibition—blocking complementary survival signals on the same cancer cell—and can also engage the immune system directly by bridging tumor-associated antigens such as EGFR with immune effector receptors like CD3 on T cells or NKG2D on NK cells, thereby initiating targeted cytotoxicity [97].